ArticleCureus2025

Immune-Related Esophagitis and Durable Response to Second-Line Treatment With Nivolumab in Stage IV Squamous Cell Esophageal Carcinoma.

Olga Meneses et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.